FDA Approves Oral Treatment for CSU

Remibrutinib is the first Bruton tyrosine kinase inhibitor approved by the FDA for chronic spontaneous urticaria.
Medscape Medical News

Source link : https://www.medscape.com/viewarticle/fda-approves-oral-btk-inhibitor-chronic-spontaneous-2025a1000q9c?src=rss

Author :

Publish date : 2025-10-01 07:09:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

FDA Approves Oral Treatment for CSU

How Do Cancer Survivors Fare After Lung Cancer Screening?

Ultraprocessed Foods Strongly Linked to Elevated MS Activity

Related Posts

Philanthropy Works to Fill Mental Health Funding Gap

The Appendicitis Dilemma: Surgery or a Simpler Solution?

How Clinicians Are Putting the Beers Alternatives to Work

Colchicine Linked to Better Cardiovascular Outcomes in Gout

A Novel Way to Spot Gait Problems in Parkinson’s

‘Addictive’ UPF Intake More Prevalent in Older US Adults

Philanthropy Works to Fill Mental Health Funding Gap

The Appendicitis Dilemma: Surgery or a Simpler Solution?

How Clinicians Are Putting the Beers Alternatives to Work

Colchicine Linked to Better Cardiovascular Outcomes in Gout

A Novel Way to Spot Gait Problems in Parkinson’s

‘Addictive’ UPF Intake More Prevalent in Older US Adults

Rising CVD Risks: Pregnancy an Opportunity to Screen

NHS needs up to £3bn extra to avoid cuts, health leaders warn

Categories

Archives